{
    "doi": "https://doi.org/10.1182/blood.V120.21.3746.3746",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2309",
    "start_url_page_num": 2309,
    "is_scraped": "1",
    "article_title": "Secondary Malignancies in CML Patients \u2013 Data From the German CML Study IV ",
    "article_date": "November 16, 2012",
    "session_type": "632. Chronic Myeloid Leukemia - Therapy: Poster III",
    "topics": [
        "neoplasm metastasis",
        "cancer",
        "imatinib mesylate",
        "protein-tyrosine kinase inhibitor",
        "neoplasms",
        "follow-up",
        "interferon-alpha",
        "basal cell carcinoma",
        "brain tumors",
        "chronic b-cell leukemias"
    ],
    "author_names": [
        "Manuel Barreto Miranda, MD",
        "Michael Lauseker",
        "Ulrike Proetel, MD",
        "Annette Schreiber, MD",
        "Benjamin Hanfstein, MD",
        "Gabriela M. Baerlocher, MD",
        "Dominik Heim, MD",
        "Gerhard Ehninger",
        "Dieter K. Hossfeld, MD",
        "Hans-Jochem Kolb, MD",
        "Stefan W. Krause, MD",
        "Christoph Nerl, MD",
        "Hermann Einsele",
        "Mathias Ha\u0308nel, MD",
        "Jolanta Dengler, MD",
        "Christiane Falge, MD",
        "Lothar Kanz, MD",
        "Andreas Neubauer, MD",
        "Michael Kneba, MD, PhD",
        "Frank Stegelmann, MD",
        "Michael Pfreundschuh, MD",
        "Cornelius F. Waller, MD",
        "Karsten Spiekermann, MD",
        "Wolf-Karsten Hofmann",
        "Martin C. Mu\u0308ller, MD",
        "Markus Pfirrmann",
        "Andreas Hochhaus, MD",
        "Joerg Hasford",
        "Ru\u0308diger Hehlmann, MD",
        "Susanne Saussele, MD"
    ],
    "author_affiliations": [
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin, Mannheim, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "Universita\u0308tsklinik fu\u0308r Ha\u0308matologie, Inselspital, Bern, Switzerland, "
        ],
        [
            "Behandlungszentrum Stammzelltransplantation, Universita\u0308tsspital, Basel, Switzerland, "
        ],
        [
            "Universita\u0308tsklinikum Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany, "
        ],
        [
            "II. Medizinische Klinik, Universita\u0308tsklinikum Eppendorf, Hamburg, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "Medizinische Klinik 5, Universita\u0308tsklinikum, Erlangen, Germany, "
        ],
        [
            "Klinik fu\u0308r Ha\u0308matologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, Klinikum Schwabing, Mu\u0308nchen, Germany, "
        ],
        [
            "Medizinische Klinik II, Universita\u0308tsklinikum, Wu\u0308rzburg, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin III, Klinikum, Chemnitz, Germany, "
        ],
        [
            "Innere Medizin V, Universita\u0308tsklinikum, Heidelberg, Germany, "
        ],
        [
            "Medizinische Klinik 5, Klinikum Nord, Nu\u0308rnberg, Germany, "
        ],
        [
            "Innere Medizin II, Universita\u0308tsklinikum, Tu\u0308bingen, Germany, "
        ],
        [
            "Klinik fu\u0308r Ha\u0308matologie, Zentrum Innere Medizin, Philipps-Universita\u0308t, Marburg, Germany, "
        ],
        [
            "II. Medizinische Klinik und Poliklinik, Universita\u0308tsklinikum Schleswig-Holstein, Kiel, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin III, Universita\u0308tsklinikum, Ulm, Germany, "
        ],
        [
            "Innere Medizin I, Universita\u0308tsklinikum des Saarlandes, Homburg, Germany, "
        ],
        [
            "Innere Medizin 1, Universita\u0308tsklinikum, Freiburg, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin II, Universita\u0308tsklinikum, Jena, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universita\u0308t Heidelberg, Medizinische Fakulta\u0308t, Mannheim, Germany"
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ]
    ],
    "first_author_latitude": "49.49133414999999",
    "first_author_longitude": "8.488715",
    "abstract_text": "Abstract 3746 Introduction: The increase of overall survival in chronic myeloid leukemia (CML) requires closer long-term observation in the face of a potential carcinogenicity of tyrosine kinase inhibitors (TKIs). Preclinical studies with imatinib in rats showed neoplastic changes in kidneys, urinary bladder, urethra, preputial and clitoral glands, small intestine, parathyroid glands, adrenal glands, and nonglandular stomach. Two epidemiologic studies on patients with chronic myeloproliferative neoplasms (CMPN) and CML (Frederiksen H et al., Blood 2011; Rebora P et al., Am J Epidemiol 2010) found an increased risk of secondary malignancies compared with the general population independent of treatment. In contrast, in a recent analysis of patients with CML and CMPN treated with TKI (Verma D et al., Blood 2011) a decreased risk of secondary malignancies was reported. Aims: To further elucidate the risk of TKI treated CML patients for the development of secondary malignancies we analysed data of the CML study IV, a randomized 5-arm trial (imatinib 400 mg vs. imatinib 800 mg vs. imatinib 400 mg in combination with interferon alpha vs. imatinib 400 mg in combination with AraC vs. imatinib 400 mg after interferon failure). Patients and methods: From February 2002 to April 2012, 1551 CML patients in chronic phase were randomized, 1525 were evaluable. Inclusion criteria allowed the history of primary cancer if the disease was in stable remission. Forty-nine malignancies were reported in 43 patients before the diagnosis of CML. If relapses occurred within 5 years after diagnosis of primary cancer they were not considered for further analysis. Median follow-up was 67.5 months. Age-standardized incidence rates were calculated from the age-specific rates using the European standard population (1976). Results: In total, 67 secondary malignancies in 64 patients were found in CML patients treated with TKI (n=61) and interferon alpha only (n=3). Twelve of these patients developed neoplasms after diagnosis of a primary cancer before diagnosis of CML, 5 patients with metastases or recurrence of the first malignancy (range of diagnosis 5\u201319 years after primary cancer). Median time to secondary malignancy was 2.5 years (range 0.1\u20138.3 years). The types of neoplasms were: prostate (n=9), colorectal (n=6), lung (n=6), non Hodgkin's lymphoma (NHL; n=7), malignant melanoma (n=5), skin tumors (basalioma n=4 and squamous cell carcinoma n=1), breast (n=5), pancreas (n=4), kidney (n=4), chronic lymphocytic leukemia (n=3), head and neck (n=2), biliary (n=2), sarcoma (n=2), and esophagus, stomach, liver, vulva, uterus, brain, cancer of unknown origin (each n=1). With these numbers the age-standardized incidence rates of secondary malignancies in CML patients were calculated: 534 cases per 100,000 for men (confidence interval [350;718]), and 582 for women (confidence interval [349;817]). The incidence rates of the general population in Germany were 450 and 350 cases, respectively (\u201cKrebs in Deutschland 2007/2008\u201d, 8 th ed., Robert Koch Institute, 2012). The incidence rate of NHLs was higher for CML patients than for the general population but this is not significant. Conclusions: In our cohort, the incidence rate of secondary neoplasms in CML patients was slightly increased compared to the general population. The most common secondary malignancies in CML patients under treatment were cancers of the skin, prostate, colon, lung and NHL. Since the occurrence of secondary neoplasia increases over time, long-term follow-up of CML patients is warranted. Disclosures: Mu\u0308ller: Novartis, BMS: Consultancy, Honoraria, Research Funding. Hochhaus: Novartis, BMS, MSD, Ariad, Pfizer: Consultancy Other, Honoraria, Research Funding. Hehlmann: Novartis: Research Funding."
}